We’re developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function. Our programs targeting the NBD1, ICL4, and TMD1 regions of CFTR are complementary, and together they have the potential to deliver best-in-class efficacy to achieve best in class efficacy by normalizing CFTR function.

Discovery
Pre-Clinical
IND-Enabling
Phase 1
NBD1
SION-638
IND-Enabling
NBD1
Additional candidates
Pre-Clinical
ICL4
SION-109
IND-Enabling
ICL4
Additional Candidates
Pre-Clinical
TMD1
Candidates
Pre-Clinical